News
MLTX
18.02
-4.05%
-0.76
Buy Rating on MoonLake: Sonelokimab’s Differentiated IL‑17 Profile and Late‑Stage HS Opportunity Support $40 Target
TipRanks · 13h ago
Major Insider Move at MoonLake Immunotherapeutics Stirs Investor Attention
TipRanks · 21h ago
MoonLake CEO Jorge Santos da Silva sells USD 2.7 million shares
PUBT · 1d ago
Positive Risk-Reward and Strategic Momentum Underpin Buy Rating on MoonLake Immunotherapeutics
TipRanks · 1d ago
Weekly Report: what happened at MLTX last week (0406-0410)?
Weekly Report · 2d ago
MoonLake CFO Matthias Bodenstedt disposes of USD 1.7 million in common shares
Reuters · 5d ago
Southwest Airlines, Colliers International, and More Stocks See Action From Activist Investors
Barron‘s · 5d ago
Insmed Drug Misses Primary Goal, Program Axed
Benzinga · 04/08 11:08
MoonLake Buy Rating: Clear HS Approval Path, Priority Review Upside, and Underappreciated Multi-Indication Value
TipRanks · 04/08 10:05
Weekly Report: what happened at MLTX last week (0330-0403)?
Weekly Report · 04/06 09:12
Major Insider Move at MoonLake Immunotherapeutics Shakes Up Investor Sentiment
TipRanks · 04/03 02:01
BVF Partners reports MoonLake Immunotherapeutics share sale worth $63.33 million
Reuters · 04/02 20:49
Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA), Apellis Pharmaceuticals (APLS) and MoonLake Immunotherapeutics (MLTX)
TipRanks · 03/31 17:00
Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Neumora Therapeutics, Inc. (NMRA) and Aurinia Pharmaceuticals (AUPH)
TipRanks · 03/31 11:50
MoonLake Says Lead Drug Shows Durable Response, Eyes FDA Filing
Benzinga · 03/30 15:27
MoonLake Immunotherap Price Target Maintained With a $30.00/Share by BTIG
Dow Jones · 03/30 12:52
BTIG Reiterates Buy on MoonLake, Maintains $30 Price Target
Benzinga · 03/30 12:43
Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), AbSci (ABSI) and MaxCyte (MXCT)
TipRanks · 03/30 11:02
H.C. Wainwright Keeps Their Buy Rating on MoonLake Immunotherapeutics (MLTX)
TipRanks · 03/30 10:36
Weekly Report: what happened at MLTX last week (0323-0327)?
Weekly Report · 03/30 09:12
More
Webull provides a variety of real-time MLTX stock news. You can receive the latest news about MoonLake Immunotherapeutics through multiple platforms. This information may help you make smarter investment decisions.
About MLTX
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.